Parexel & Palantir Partner to Accelerate Clinical Trials with AI

By harnessing the power of AI and advanced analytics, the collaboration aims to revolutionize clinical trials.

Global clinical research organization Parexel has joined forces with Palantir Technologies Inc., a leading AI systems builder, in a multi-year strategic partnership aimed at leveraging AI to enhance and expedite the delivery of safe and effective clinical trials for pharmaceutical clients worldwide.

This collaboration notifies a significant step forward in the clinical research landscape. Parexel becomes the first CRO to collaborate with Palantir in utilizing AI to enhance its clinical data platform.

By harnessing Palantir's Foundry and Artificial Intelligence Platform (AIP), Parexel aims to bolster its clinical trial efficiency while upholding the highest standards of safety and regulatory compliance.

Sharing thoughts, Jonathan Shough, CIO, Parexel, said, "As we build on our application of AI to further improve clinical trial execution and advance our offerings in Real World Evidence, advanced analytics and Health Outcomes. Leveraging our internal Parexel expertise and our strategic partnership with Palantir, we have novel solutions already in use or in various stages of development that demonstrate our commitment to be a fully digital CRO."

Empowering Clinical Data Platform

Per the partnership, Parexel, known for its Parexel Precision Pathway – an end-to-end operational approach prioritizing timely delivery of clean data – is set to amplify its capabilities through this partnership.

With Palantir's advanced software, Parexel's clinical data platform will evolve into an integrated digital environment, enabling hyper-automation of manual processes, enhancing data discoverability, and extracting insights from historical trials.

D Lalarukh Haris Shaikh, executive of Life Sciences at Palantir, expressed enthusiasm about deepening the collaboration with Parexel. He emphasized Palantir's commitment to empowering Parexel in fully leveraging the capabilities of AIP and Foundry throughout their clinical processes and business operations.

Streamlining Clinical Operations

Parexel's clinical data platform, fortified by Palantir's technology, will provide real-time access to validated data for customers, fostering transparency during ongoing studies and expediting timelines from trial planning to submission.

This streamlined approach aims to enhance coordination among scientific and operational teams, driving efficiency and accelerating the drug development process.

Stephen Pyke, DIC, chief clinical data and digital officer, Parexel, and chair of the Association of Clinical Research Organization's (ACRO) AI/ML Committee, said, "Combining our end-to-end delivery model with Palantir's world-class security, governance, and artificial intelligence platform will generate strategic insights to inform drug development and accelerate time to market."

Enhancing Business Operations

According to Shaikh, this partnership will significantly accelerate Palantir's business by harnessing the value of data through ontology construction.

By tapping into Palantir's latest technology, Parexel aims to unlock new possibilities in clinical research, driving innovation and advancing the standard of care in drug development.

By harnessing the power of AI and advanced analytics, the collaboration aims to revolutionize clinical trials, empowering biopharmaceutical companies to bring safe and effective therapies to market more efficiently.